NASDAQ:XNCR - Xencor Stock Price, Forecast & News

Xencor's stock was trading at $28.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XNCR stock has increased by 1.2% and is now trading at $28.46. View which stocks have been mosted impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 2 sell ratings, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xencor.

Xencor is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Xencor.

Xencor Inc (NASDAQ:XNCR) released its quarterly earnings data on Monday, February, 24th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.05. The biopharmaceutical company had revenue of $3.52 million for the quarter, compared to analyst estimates of $6.73 million. Xencor had a return on equity of 4.23% and a net margin of 17.15%. View Xencor's earnings history.

11 brokerages have issued 1-year target prices for Xencor's shares. Their forecasts range from $21.00 to $67.00. On average, they anticipate Xencor's share price to reach $44.50 in the next year. This suggests a possible upside of 56.4% from the stock's current price. View analysts' price targets for Xencor.

Media stories about XNCR stock have trended extremely negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Xencor earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutXencor.

Xencor saw a decrease in short interest in March. As of March 13th, there was short interest totaling 4,689,100 shares, a decrease of 10.9% from the February 27th total of 5,260,000 shares. Based on an average daily volume of 525,300 shares, the short-interest ratio is currently 8.9 days. Currently, 8.4% of the company's stock are short sold. View Xencor's Current Options Chain.

Some companies that are related to Xencor include Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO) and Blueprint Medicines (BPMC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Cypress Semiconductor (CY), Bank of America (BAC), Fossil Group (FOSL), Apollo Global Management (APO), Exelixis (EXEL), Intel (INTC), Abercrombie & Fitch (ANF), Ciena (CIEN) and Immunomedics (IMMU).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (3.50%), Norges Bank (1.80%), Geode Capital Management LLC (1.21%), Goldman Sachs Group Inc. (1.03%) and Loomis Sayles & Co. L P (1.03%). Company insiders that own Xencor stock include Bassil I Dahiyat, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III, Paul A Foster and Ronin Capital, Llc. View institutional ownership trends for Xencor.

XNCR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, PNC Financial Services Group Inc., Franklin Resources Inc., Franklin Resources Inc., Rafferty Asset Management LLC, First Trust Advisors LP, Citigroup Inc., and Arizona State Retirement System. Company insiders that have sold Xencor company stock in the last year include John J Kuch, John R Desjarlais, John S Stafford III, and Ronin Capital, Llc. View insider buying and selling activity for Xencor.

XNCR stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Man Group plc, Raymond James & Associates, Los Angeles Capital Management & Equity Research Inc., Great West Life Assurance Co. Can, and Panagora Asset Management Inc.. View insider buying and selling activity for Xencor.

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XNCR stock can currently be purchased for approximately $28.46.

Xencor has a market capitalization of $1.62 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe. View additional information about Xencor.

The official website for Xencor is http://www.xencor.com/.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]